ReWalk Robotics Stock Forecast, Price & News

-0.02 (-1.13 %)
(As of 06/24/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume421,995 shs
Average Volume2.33 million shs
Market Capitalization$80.71 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive RWLK News and Ratings via Email

Sign-up to receive the latest news and ratings for ReWalk Robotics and its competitors with MarketBeat's FREE daily newsletter.

ReWalk Robotics logo

About ReWalk Robotics

ReWalk Robotics Ltd., a medical device company, designs, develops, and commercializes wearable robotic exoskeletons for individuals with mobility impairments or other medical conditions in Israel, the United States, Europe, the Asia-Pacific, Latin America, and Africa. It offers ReWalk Personal and ReWalk Rehabilitation for spinal cord injuries and everyday use by paraplegic individuals at home and in communities; ReStore, a soft exo-suit intended for used in the rehabilitation of individuals with lower limb disability due to stroke; and MyoCycle and MediTouch tutor movement biofeedback devices for use at home or in clinic. It markets and sells its products directly to third party payers, institutions, and individuals, as well as through distributors. The company was formerly known as Argo Medical Technologies Ltd. and changed its name to ReWalk Robotics Ltd. ReWalk Robotics Ltd. was founded in 2001 and is headquartered in Yokneam Ilit, Israel.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.45 out of 5 stars

Medical Sector

662nd out of 2,118 stocks

Surgical Appliances & Supplies Industry

13th out of 40 stocks

Analyst Opinion: 3.5Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

ReWalk Robotics (NASDAQ:RWLK) Frequently Asked Questions

Is ReWalk Robotics a buy right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ReWalk Robotics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ReWalk Robotics stock.
View analyst ratings for ReWalk Robotics
or view top-rated stocks.

What stocks does MarketBeat like better than ReWalk Robotics?

Wall Street analysts have given ReWalk Robotics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but ReWalk Robotics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting ReWalk Robotics?

ReWalk Robotics saw a decrease in short interest in May. As of May 14th, there was short interest totaling 426,500 shares, a decrease of 43.1% from the April 29th total of 749,700 shares. Based on an average daily volume of 1,730,000 shares, the short-interest ratio is presently 0.2 days.
View ReWalk Robotics' Short Interest

When is ReWalk Robotics' next earnings date?

ReWalk Robotics is scheduled to release its next quarterly earnings announcement on Wednesday, August 11th 2021.
View our earnings forecast for ReWalk Robotics

How were ReWalk Robotics' earnings last quarter?

ReWalk Robotics Ltd. (NASDAQ:RWLK) announced its earnings results on Tuesday, May, 11th. The medical device company reported ($0.08) EPS for the quarter, missing analysts' consensus estimates of ($0.07) by $0.01. The medical device company earned $1.32 million during the quarter. ReWalk Robotics had a negative net margin of 246.47% and a negative trailing twelve-month return on equity of 40.84%.
View ReWalk Robotics' earnings history

How has ReWalk Robotics' stock price been impacted by Coronavirus?

ReWalk Robotics' stock was trading at $0.6050 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, RWLK shares have increased by 189.3% and is now trading at $1.75.
View which stocks have been most impacted by COVID-19

What price target have analysts set for RWLK?

1 analysts have issued twelve-month target prices for ReWalk Robotics' stock. Their forecasts range from $3.50 to $3.50. On average, they expect ReWalk Robotics' share price to reach $3.50 in the next twelve months. This suggests a possible upside of 100.0% from the stock's current price.
View analysts' price targets for ReWalk Robotics
or view top-rated stocks among Wall Street analysts.

Who are ReWalk Robotics' key executives?

ReWalk Robotics' management team includes the following people:
  • Mr. Lawrence J. Jasinski, CEO & Director (Age 64, Pay $555.79k)
  • Mr. Ori Gon, Chief Financial Officer (Age 39, Pay $303.42k)
  • Ms. Miri Pariente, VP of Operations, Regulatory & Quality (Age 44)
  • Mr. Andy Dolan, VP of Marketing & Reimbursement
  • Ms. Judy Kula, VP of Customer Service, HR & Bus. Affairs
  • Mr. Ami Kraft, Exec. Advisor to the CEO (Age 78)

Who are some of ReWalk Robotics' key competitors?

What other stocks do shareholders of ReWalk Robotics own?

What is ReWalk Robotics' stock symbol?

ReWalk Robotics trades on the NASDAQ under the ticker symbol "RWLK."

Who are ReWalk Robotics' major shareholders?

ReWalk Robotics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Armistice Capital LLC (4.14%), Morgan Stanley (2.33%), Virtu Financial LLC (0.12%), Renaissance Technologies LLC (0.12%), Dimensional Fund Advisors LP (0.08%) and Rhumbline Advisers (0.05%).
View institutional ownership trends for ReWalk Robotics

Which institutional investors are selling ReWalk Robotics stock?

RWLK stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, and Virtu Financial LLC.
View insider buying and selling activity for ReWalk Robotics
or view top insider-selling stocks.

Which institutional investors are buying ReWalk Robotics stock?

RWLK stock was acquired by a variety of institutional investors in the last quarter, including Morgan Stanley, Armistice Capital LLC, Dimensional Fund Advisors LP, Rhumbline Advisers, HighTower Advisors LLC, Sadoff Investment Management LLC, Sigma Planning Corp, and Jane Street Group LLC.
View insider buying and selling activity for ReWalk Robotics
or or view top insider-buying stocks.

How do I buy shares of ReWalk Robotics?

Shares of RWLK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ReWalk Robotics' stock price today?

One share of RWLK stock can currently be purchased for approximately $1.75.

How much money does ReWalk Robotics make?

ReWalk Robotics has a market capitalization of $80.71 million and generates $4.39 million in revenue each year. The medical device company earns $-12,980,000.00 in net income (profit) each year or ($0.82) on an earnings per share basis.

How many employees does ReWalk Robotics have?

ReWalk Robotics employs 49 workers across the globe.

What is ReWalk Robotics' official website?

The official website for ReWalk Robotics is

Where are ReWalk Robotics' headquarters?

ReWalk Robotics is headquartered at 3 Hatnufa Street Floor 6, Yokneam Ilit L3, 2069203.

How can I contact ReWalk Robotics?

ReWalk Robotics' mailing address is 3 Hatnufa Street Floor 6, Yokneam Ilit L3, 2069203. The medical device company can be reached via phone at 972-4959-0123 or via email at [email protected]

This page was last updated on 6/25/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.